3 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 3 Phase 3, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Essential Thrombocythaemia: new trials by email Literature Review of Essential Thrombocythaemia trials Research Report on Essential Thrombocythaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial STP938 - Essential Thrombocythaemia | Phase 2 | Recruiting | Step Pharma, SAS | 50 | 2025-06-18 | 2026-06-16 |
| Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History NGS testing, NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies - Polycythemia Vera, Essential Thrombocythaemia | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 496 | 2025-05-21 | 2025-05-15 |
| MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms Myelofibrosis (MF), Polycythemia Vera | Recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1190 | 2025-02-17 | 2026-10-07 | |
| A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Ropeginterferon alfa-2b (BESREMi®) - Essential Thrombocythaemia | Phase 3 | Active not recruiting | AOP Orphan Pharmaceuticals AG | 117 | 2023-12-04 | 2024-12-19 |
| Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Anagrelide retard, Placebo - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 146 | 2010-12-01 | 2016-05-26 |
| The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) anagrelide hydrochloride - Essential Thrombocythaemia | Phase 2 | Completed | Shire | 24 | 2006-11-13 | 2021-06-29 |
| Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Anagrelide, Hydroxyurea - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 2002-09-01 | 2010-10-06 |
Thrombocythemia, Essential (7) · Polycythemia Vera (2) · Primary Myelofibrosis (2) · Thrombocytosis (1)
Blood Coagulation Disorders (7) · Blood Platelet Disorders (7) · Bone Marrow Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Myeloproliferative Disorders (7) · Thrombocytosis (6) · Bone Marrow Neoplasms (2) · Hematologic Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2)
anagrelide (2) · Hydroxyurea (1) · Mutation (1)
AOP Orphan Pharmaceuticals AG (3) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Shire (1) · Step Pharma, SAS (1)
Austria (3) · France (3) · Italy (3) · Poland (3) · Czechia (2) · Germany (2) · Hungary (2) · Lithuania (2) · Romania (2) · Spain (2) · United Kingdom (2) · Bulgaria (1) · Croatia (1) · Greece (1) · Russia (1)
Barbara Grohmann-Izay, MD (1) · Maureen Higgins (1)
2004 (1)